VivoSeq
Other

Idiopathic Hypersomnia

21

Pipeline Programs↗

11

Active Trials↗

9

Companies Involved↗

Idiopathic Hypersomnia is an emerging landscape with 21 programs across 9 companies. The most active players are Balance Therapeutics, Centessa Pharmaceuticals (UK) Limited, Zevra Therapeutics. 4 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

19/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Balance Therapeutics

2 programs

Phase 2C

Centessa Pharmaceuticals (UK) Limited

1 program

Phase 2Z

Zevra Therapeutics

1 program

Phase 2A

Axsome Therapeutics, Inc.

1 program

Phase 2Takeda logo

Takeda

2 programs

Phase 2H

Harmony Biosciences Management, Inc.

4 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

21

clinical trials

Completed9 · 43%
Recruiting8 · 38%
Not yet recruiting2 · 10%
Active, not recruiting1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

21 trials

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Recruiting·CCentessa Pharmaceuticals (UK) Limited·Phase 2·NCT06752668·96 enrolled
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
Recruiting·MMayo Clinic·Phase 4·NCT05837091·30 enrolled
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Recruiting·Takeda logoTakeda·Phase 2·NCT06812078·96 enrolled
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Recruiting·CCentessa Pharmaceuticals (UK) Limited·Phase 2·NCT07096674·90 enrolled
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Recruiting·AAlkermes, Inc.·Phase 2/3·NCT06767683·256 enrolled
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) Followed by an Open-label Extension
Recruiting·HHarmony Biosciences Management, Inc.·Phase 3·NCT07500090·248 enrolled
A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions
Recruiting·Takeda logoTakeda·Preclinical·NCT07646678·500 enrolled
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)
Recruiting·AAlkermes, Inc.·Phase 2·NCT06843590·126 enrolled
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Active, not recruiting·AAvadel·Phase 3·NCT06525077·150 enrolled
Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome
Not yet recruiting·SStanford University·Phase 4·NCT07077278·25 enrolled
Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.
Not yet recruiting·UUniversity Hospital, Montpellier·Phase 2·NCT06590662·60 enrolled
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT03533114·154 enrolled
Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia
Completed·EEmory University·Phase 2·NCT03772314·44 enrolled
A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 4·NCT05875974·207 enrolled
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Completed·HHarmony Biosciences Management, Inc.·Phase 3·NCT05156047·214 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)